CA2518328C - Methode de preparation de nouveaux facteurs de transcription et utilisation connexe - Google Patents

Methode de preparation de nouveaux facteurs de transcription et utilisation connexe Download PDF

Info

Publication number: CA2518328C
Authority: CA; Canada
Prior art keywords: group; pharmaceutical composition; ascochlorin; acetal compound; mac
Prior art date: 2005-09-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2518328A

Other languages

English (en)

Other versions

CA2518328A1 (fr

Inventor

Takeshi Kitahara

Hidenori Watanabe

Kunio Ando

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

NRL Pharma Inc

Original Assignee

NRL Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-07

Filing date

2005-09-07

Publication date

2012-07-31

2005-09-07 Application filed by NRL Pharma Inc filed Critical NRL Pharma Inc

2005-09-07 Priority to CA2518328A priority Critical patent/CA2518328C/fr

2007-03-07 Publication of CA2518328A1 publication Critical patent/CA2518328A1/fr

2012-07-31 Application granted granted Critical

2012-07-31 Publication of CA2518328C publication Critical patent/CA2518328C/fr

2025-09-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 22
108091023040 Transcription factor Proteins 0.000 title description 7
102000040945 Transcription factor Human genes 0.000 title description 7
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims abstract description 44
SETVRSKZJJWOPA-FLDGXQSCSA-N ascochlorin Chemical compound C[C@@H]1CCC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O SETVRSKZJJWOPA-FLDGXQSCSA-N 0.000 claims abstract description 33
SHZXWVNJUPKTJN-UHFFFAOYSA-N Ascochlorin Natural products CC1CCC(=O)C(C)C1C=CC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O SHZXWVNJUPKTJN-UHFFFAOYSA-N 0.000 claims abstract description 28
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
208000011580 syndromic disease Diseases 0.000 claims abstract description 8
208000037976 chronic inflammation Diseases 0.000 claims abstract description 7
230000006020 chronic inflammation Effects 0.000 claims abstract description 7
208000037803 restenosis Diseases 0.000 claims abstract description 5
206010028665 Myxoedema Diseases 0.000 claims abstract description 4
208000003786 myxedema Diseases 0.000 claims abstract description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 29
-1 acetal compound Chemical class 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 12
239000002246 antineoplastic agent Substances 0.000 claims description 11
206010012601 diabetes mellitus Diseases 0.000 claims description 10
206010020772 Hypertension Diseases 0.000 claims description 9
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
VGYPZLGWVQQOST-UHFFFAOYSA-N Ascofuranone Natural products OC=1C(Cl)=C(C)C(C=O)=C(O)C=1CC=C(C)CCC=C(C)C1CC(=O)C(C)(C)O1 VGYPZLGWVQQOST-UHFFFAOYSA-N 0.000 claims description 7
VGYPZLGWVQQOST-JUERRSSISA-N ascofuranone Chemical compound OC=1C(Cl)=C(C)C(C=O)=C(O)C=1C\C=C(/C)CC\C=C(/C)[C@@H]1CC(=O)C(C)(C)O1 VGYPZLGWVQQOST-JUERRSSISA-N 0.000 claims description 7
229940126585 therapeutic drug Drugs 0.000 claims description 7
230000001225 therapeutic effect Effects 0.000 claims description 7
ZLAQYJKDQSZARB-FLDGXQSCSA-N 5-chloro-2,4-dihydroxy-6-methyl-3-[(2e,4e)-3-methyl-5-[(1s,2r,6r)-1,2,6-trimethyl-5-oxocyclohex-3-en-1-yl]penta-2,4-dienyl]benzaldehyde Chemical compound C[C@@H]1C=CC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O ZLAQYJKDQSZARB-FLDGXQSCSA-N 0.000 claims description 5
ZLAQYJKDQSZARB-UHFFFAOYSA-N Cylindrochlorin Natural products CC1C=CC(=O)C(C)C1(C)C=CC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O ZLAQYJKDQSZARB-UHFFFAOYSA-N 0.000 claims description 5
230000002194 synthesizing effect Effects 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
239000003529 anticholesteremic agent Substances 0.000 claims description 3
229940127226 anticholesterol agent Drugs 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
150000003934 aromatic aldehydes Chemical class 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
229940043274 prophylactic drug Drugs 0.000 claims 2
150000001875 compounds Chemical class 0.000 abstract description 27
239000003814 drug Substances 0.000 abstract description 26
206010028980 Neoplasm Diseases 0.000 abstract description 15
125000003172 aldehyde group Chemical group 0.000 abstract description 14
238000002560 therapeutic procedure Methods 0.000 abstract description 12
201000011510 cancer Diseases 0.000 abstract description 10
230000000694 effects Effects 0.000 abstract description 8
LJFQTUKKYWDRAT-UHFFFAOYSA-N 2,4-dihydroxy-6-methylbenzaldehyde Chemical group CC1=CC(O)=CC(O)=C1C=O LJFQTUKKYWDRAT-UHFFFAOYSA-N 0.000 abstract description 6
239000003054 catalyst Substances 0.000 abstract description 6
230000002401 inhibitory effect Effects 0.000 abstract description 6
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 abstract description 3
210000001367 artery Anatomy 0.000 abstract description 3
230000001172 regenerating effect Effects 0.000 abstract description 3
230000002792 vascular Effects 0.000 abstract description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
241000699670 Mus sp. Species 0.000 description 26
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
210000004369 blood Anatomy 0.000 description 24
239000008280 blood Substances 0.000 description 24
150000001241 acetals Chemical class 0.000 description 22
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
241000700159 Rattus Species 0.000 description 20
239000000203 mixture Substances 0.000 description 20
239000000243 solution Substances 0.000 description 20
241000699666 Mus <mouse, genus> Species 0.000 description 19
229940079593 drug Drugs 0.000 description 18
208000001072 type 2 diabetes mellitus Diseases 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
102000004877 Insulin Human genes 0.000 description 14
108090001061 Insulin Proteins 0.000 description 14
230000009471 action Effects 0.000 description 14
229940125396 insulin Drugs 0.000 description 14
235000005911 diet Nutrition 0.000 description 13
230000037213 diet Effects 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
230000037396 body weight Effects 0.000 description 12
239000007864 aqueous solution Substances 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
208000031225 myocardial ischemia Diseases 0.000 description 10
239000005495 thyroid hormone Substances 0.000 description 10
229940036555 thyroid hormone Drugs 0.000 description 10
208000008589 Obesity Diseases 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
235000020824 obesity Nutrition 0.000 description 9
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
210000000593 adipose tissue white Anatomy 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
230000034994 death Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
235000020188 drinking water Nutrition 0.000 description 8
239000003651 drinking water Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
206010022489 Insulin Resistance Diseases 0.000 description 7
230000001747 exhibiting effect Effects 0.000 description 7
238000005755 formation reaction Methods 0.000 description 7
238000000746 purification Methods 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000001093 anti-cancer Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000036772 blood pressure Effects 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
201000010099 disease Diseases 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
206010003210 Arteriosclerosis Diseases 0.000 description 5
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
208000035150 Hypercholesterolemia Diseases 0.000 description 5
229960001138 acetylsalicylic acid Drugs 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
208000028867 ischemia Diseases 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
SWTCCCJQNPGXLQ-UHFFFAOYSA-N 1-(1-butoxyethoxy)butane Chemical compound CCCCOC(C)OCCCC SWTCCCJQNPGXLQ-UHFFFAOYSA-N 0.000 description 4
206010002329 Aneurysm Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000007547 defect Effects 0.000 description 4
230000007613 environmental effect Effects 0.000 description 4
239000000945 filler Substances 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
210000004153 islets of langerhan Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
229940086542 triethylamine Drugs 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 3
VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 3
108010010234 HDL Lipoproteins Proteins 0.000 description 3
102000015779 HDL Lipoproteins Human genes 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
239000002262 Schiff base Substances 0.000 description 3
150000004753 Schiff bases Chemical class 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
239000012346 acetyl chloride Substances 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
229960004486 desoxycorticosterone acetate Drugs 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000003975 mesenteric artery Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
235000000891 standard diet Nutrition 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XUAAAHFMBMDZCQ-UMXIGZEWSA-N 5-chloro-2-hydroxy-4-methoxy-6-methyl-3-[(2e,4e)-3-methyl-5-[(1r,2r,6r)-1,2,6-trimethyl-3-oxocyclohexyl]penta-2,4-dienyl]benzaldehyde Chemical compound COC1=C(Cl)C(C)=C(C=O)C(O)=C1C\C=C(/C)\C=C\[C@]1(C)[C@@H](C)C(=O)CC[C@H]1C XUAAAHFMBMDZCQ-UMXIGZEWSA-N 0.000 description 2
241000220479 Acacia Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
241000208125 Nicotiana Species 0.000 description 2
235000002637 Nicotiana tabacum Nutrition 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000003377 acid catalyst Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000000654 additive Substances 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
230000032683 aging Effects 0.000 description 2
125000003158 alcohol group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000023852 carbohydrate metabolic process Effects 0.000 description 2
235000021256 carbohydrate metabolism Nutrition 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
239000005516 coenzyme A Substances 0.000 description 2
229940093530 coenzyme a Drugs 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
239000013078 crystal Substances 0.000 description 2
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
201000010063 epididymitis Diseases 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000036449 good health Effects 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229940087646 methanolamine Drugs 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
229940105631 nembutal Drugs 0.000 description 2
102000006255 nuclear receptors Human genes 0.000 description 2
108020004017 nuclear receptors Proteins 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
208000011906 peptic ulcer disease Diseases 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000036962 time dependent Effects 0.000 description 2
231100000816 toxic dose Toxicity 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
238000011282 treatment Methods 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
208000004611 Abdominal Obesity Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000036490 Arterial inflammations Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000035470 Disorder of energy metabolism Diseases 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
206010039020 Rhabdomyolysis Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
238000006359 acetalization reaction Methods 0.000 description 1
230000000397 acetylating effect Effects 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
238000005910 aminocarbonylation reaction Methods 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical class [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000035622 drinking Effects 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000009207 exercise therapy Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
238000009472 formulation Methods 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
230000007574 infarction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
108010022197 lipoprotein cholesterol Proteins 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000019691 monocalcium phosphate Nutrition 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
238000007344 nucleophilic reaction Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000005871 repellent Substances 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000004026 tunica intima Anatomy 0.000 description 1
230000007306 turnover Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000009736 wetting Methods 0.000 description 1
210000000636 white adipocyte Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
- C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA2518328A 2005-09-07 2005-09-07 Methode de preparation de nouveaux facteurs de transcription et utilisation connexe Expired - Fee Related CA2518328C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2518328A CA2518328C (fr)	2005-09-07	2005-09-07	Methode de preparation de nouveaux facteurs de transcription et utilisation connexe

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2518328A CA2518328C (fr)	2005-09-07	2005-09-07	Methode de preparation de nouveaux facteurs de transcription et utilisation connexe

Publications (2)

Publication Number	Publication Date
CA2518328A1 CA2518328A1 (fr)	2007-03-07
CA2518328C true CA2518328C (fr)	2012-07-31

Family

ID=37871968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2518328A Expired - Fee Related CA2518328C (fr)	2005-09-07	2005-09-07	Methode de preparation de nouveaux facteurs de transcription et utilisation connexe

Country Status (1)

Country	Link
CA (1)	CA2518328C (fr)

2005
- 2005-09-07 CA CA2518328A patent/CA2518328C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2518328A1 (fr)	2007-03-07

Legal Events

Date	Code	Title	Description
2010-04-27	EEER	Examination request
2020-10-20	MKLA	Lapsed	Effective date: 20200908

Publication	Publication Date	Title
EP2514739B1 (fr)	2016-12-21	Acide bêta-phényl-alpha-hydroxy propanoïque substitué, procédé de synthèse et son utilisation
EP1176134A1 (fr)	2002-01-30	Ligands de recepteurs nucleaires ppar
IL228630A (en)	2017-03-30	Compounds for the treatment of metabolic syndrome and intermediates for the synthesis of these compounds
JP2814950B2 (ja)	1998-10-27	血糖降下剤
SU1151209A3 (ru)	1985-04-15	Способ получени @ -токофериловых эфиров 5-замещенной пиколиновой кислоты
JPH09124684A (ja)	1997-05-13	プロピオフェノン誘導体およびその製法
US7432306B2 (en)	2008-10-07	Method for preparing novel transcription factors and use
JPH1067656A (ja)	1998-03-10	細胞接着抑制剤
CN113181160A (zh)	2021-07-30	异硫氰酸酯类化合物的用途
JP4545463B2 (ja)	2010-09-15	新規転写因子の製造法及び用途
CN113214097B (zh)	2022-08-30	治疗阿尔茨海默病的化合物
RU2002102495A (ru)	2003-10-10	Новые производные ксантона, их получение и применение в качестве лекарственного средства
CA2516698C (fr)	2012-01-31	Nouveau facteur de transcription, son procede de production et son utilisation
US4510159A (en)	1985-04-09	(+)-Cyanidan-3-ol derivatives, pharmaceutical preparations that contain such compounds, and the use of the latter to treat liver or venous diseases
JP2847695B2 (ja)	1999-01-20	血糖降下剤
EP1481670A1 (fr)	2004-12-01	Composition pharmaceutique destinee au diagnostic, a la prevention ou au traitement d'un syndrome multifactoriel
EP3842410A1 (fr)	2021-06-30	Composé d'acide fibrique et son utilisation médicale
JPH1121243A (ja)	1999-01-26	医薬組成物
US4073910A (en)	1978-02-14	Method for treatment of diabetes
US6127419A (en)	2000-10-03	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
JP3491711B2 (ja)	2004-01-26	プリン誘導体及び炎症性疾患の抑制剤
SU1068035A3 (ru)	1984-01-15	Способ получени полизамещенных эфиров 4-алкиламинобензойной кислоты
JPS632546B2 (fr)	1988-01-19
HK1177929B (en)	2018-02-09	Substituted beta-phenyl-alpha-hydroxy propanoic acid, synthesis method and use thereof
HK1177929A (en)	2013-08-30	Substituted beta-phenyl-alpha-hydroxy propanoic acid, synthesis method and use thereof